Related Experiment Video

Updated: Sep 10, 2025

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

6.7K

Anti-inflammatory pharmacotherapy in patients with cardiovascular disease

Simone Finocchiaro1, Placido Maria Mazzone1, Nicola Ammirabile1

  • 1Division of Cardiology, Azienda Ospedaliero-Universitaria Policlinico 'G. Rodolico - San Marco,' University of Catania, Via Santa Sofia, 78, Catania 95123, Italy.

European Heart Journal. Cardiovascular Pharmacotherapy
|August 19, 2025
PubMed

Insights

Inflammation plays a key role in cardiovascular disease (CVD). While anti-inflammatory drugs show promise, further research is needed to optimize their use and develop targeted therapies for better CVD management.

Area of Science:

  • Cardiology
  • Immunology
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) is a leading cause of death globally.
  • Inflammation is a critical factor in the development and progression of CVD.
  • Elevated inflammatory markers are linked to CVD severity and poor outcomes.

Purpose of the Study:

  • To review the role of inflammation in CVD.
  • To evaluate current and emerging anti-inflammatory therapies for cardiovascular conditions.
  • To discuss future directions in managing CVD through inflammation control.

Main Methods:

  • Literature review of studies on inflammation and CVD.
  • Analysis of clinical trial data for anti-inflammatory agents like colchicine and interleukin inhibitors.
  • Exploration of novel therapeutic strategies including immune-modulatory and RNA-based interventions.

Main Results:

  • Colchicine shows potential but has limitations post-myocardial infarction.
  • Monoclonal antibodies targeting interleukins demonstrate biological efficacy but lack approval for CVD.
  • Emerging therapies aim for selective inflammation reduction with lower immunosuppression risks.

Conclusions:

  • Inflammation is a crucial therapeutic target in cardiovascular disease.
  • Personalized, multi-targeted approaches integrating inflammation control with other therapies are the future.
  • Inflammation management may become central to CVD treatment strategies.

Keywords:
Anti-inflammatoryCardiovascular diseasePharmacotherapy

More Related Videos

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish07:50

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish

Published on: July 16, 2012

14.3K
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.4K

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
189
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
676
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
751
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
29